patient

Oral Decitabine/Cedazuridine Plus Venetoclax Yields 91% ORR in High-Risk MDS and CMML

Original Publication Date
Article Source
External Web Content

Key Takeaways The combination therapy achieved a 91% overall response rate, with 45% complete remission and 46% marrow complete remission rates. Median overall survival was 30 months, with 1- and 3-year survival rates of 68.8% and 40.7%, respectively. SHOW MORE Decitabine…

ASH 2024 Research Summaries (Aplastic Anemia and PNH)

This publication offers summaries of selected abstracts presented at the Annual Meeting of the American Hematology Society held in December 2024. It provides new and updated information about research into the diagnosis…

Tara Lin, MD, PhD

Institution
University of Kansas Medical Center
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
About

Dr. Lin received her undergraduate degree from the University of Virginia and her MD from the Medical College of Virginia/Virginia Commonwealth University. She earned a Master of Science degree in Clinical Research from Tulane University. She completed Internal Medicine residency at the University of Maryland and Medical Oncology Fellowship at Johns Hopkins. She then completed a post-doctoral fellowship at UCLA in the laboratory of Dr. Kathleen Sakamoto with a focus on leukemia stem cells. She served on the faculty in Hematology/Oncology at the Louisiana State University Health Sciences Center

“My labs didn’t tell the whole story” Jen’s Aplastic Anemia Journey

Jen had a great life. She was married with two children, and she’s just transitioned from teaching to school counseling. At 41, life was busy yet wonderful.

Her symptoms were unusual, but not alarming. The leg pain was new, as was the bruising. Then fatigue set in, far beyond usual tiredness from her schedule. A visit to the doctor did not offer a definitive diagnosis.  They suggested it was her condition with Hashimoto's thyroiditis, but with the new bruising, they ordered labs. It was February 2022.

ASH 2024 Research Summaries (MDS and AML)

This publication offers summaries of selected abstracts presented at the Annual Meeting of the American Hematology Society held in December 2024. It provides new and updated information about research into the diagnosis…

ASH 2025 Updates: Aplastic Anemia and PNH Webinar

Thumbnail for video Watch Now

Topic(s)
Aplastic Anemia
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Presenter(s)
Taha Bat, MD
In this webinar, Dr. Taha Bat discusses research most relevant to patients reported over the past year on the biology and treatment for Aplastic Anemia and PNH. The studies were presented at the American Society of Hematology (ASH) 2025 meeting. These findings will be explained…

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.